Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
SYNAREL (nafarelin acetate) is a GnRH agonist administered as a metered nasal spray that suppresses gonadotropin secretion. It is indicated for endometriosis and precocious puberty, working by desensitizing pituitary GnRH receptors to reduce sex hormone production. The nasal route enables non-invasive dosing with rapid systemic absorption.
Product is in late-stage lifecycle with minimal Part D volume, indicating a contracting commercial footprint and likely reduced team investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SYNAREL offers experience in late-lifecycle portfolio management, generic competition strategies, and niche market focus. Career growth is limited by flat commercial trajectory; roles emphasize cost containment, prescriber retention, and managed care negotiation rather than growth marketing.
Worked on SYNAREL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo